Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis

Study Design Location Study period Treatment groups No. of patients Median dose (g/d) Median duration (d) ICU admission % Definition of mortality
Lee 2011 [13] SC retrospective PS-matched case- control study South Korea 2004–2009 CFZ 49 NR 17 NR 30-day over mortality
NAF 84 NR 15 NR 90-day SAB-related mortality
Paul 2011 [14] SC retrospective cohort study Israel 1988–1994 & 1999–2007 CFZ 72 NR NR 5.2 30-day all-cause mortality
CLX 281 NR NR 90-day mortality
Renaud 2011 [15] SC retrospective cohort study Singapore 2009 CFZ 14 2 NR NR 30-day mortality
CLX 13 2–8 NR NR
Li 2014 [16] MC retrospective cohort study USA 2008–2012 CFZ 59 6 31 7 30-day all-cause mortality
OXA 34 12 39 18 90-day all-cause mortality
Bai 2015 [17] MC retrospective PS-matched cohort study Canada 2007–2010 CFZ 105 3 NR 10 90-day mortality
CLX 249 12 NR 18
Rao 2015 [18] MC retrospective cohort study USA 2010–2013 CFZ 103 6 29 41.8 All-cause in-hospital mortality
OXA 58 12 32.5 32.8
Pollett 2016 [19] SC prospective PS-matched cohort study USA 2008–2013 CFZ 70 NR 20 13 90-day all-cause mortality
NAF 30 NR 12 27
Flynt 2017 [20] MC retrospective cohort study USA 2013–2015 CFZ 68 6 NR NR 30-day all-cause mortality
NAF 81 12 NR NR
McDanel 2017 [21] MC retrospective cohort study USA 2003–2010 CFZ 1163 NR NR 15 30-day all-cause mortality
NAF/ OXA 2004 NR NR 19 90-day all-cause mortality
Lee 2018 [22] MC prospective PS-matched cohort study South Korea 2013–2015 CFZ 79 NR NR NR 90-day all-cause mortality
NAF 163 NR NR NR 30-day all-cause mortality
  1. CFZ cefazolin, CLX cloxacillin, MC multicenter, NAF nafcillin, NR not reported, OXA oxacillin, PS propensity score, SC single center